Opinion

Redesigning supply chains could change the shape of bio/pharma

Specialty pharmacies are competing to position themselves as the best partners for manufacturers dealing with high-touch, high-risk products

Today’s evolving healthcare environment calls for more collaboration in bringing drugs to market

GSK invests in online resources to address ‘the whole patient’

International efforts to standardize guidelines for observational research could move the entire field forward

Just as the pharma industry is feeling price and margin pressure, so are wholesalers in today’s healthcare marketplace

Both promise and peril exist for drugmakers in working with diagnostic tests to commercialize new medications or refine the applicability of existing ones

Not all managed care plans have the same influence on overall prescribing behavior, and not all geographies operate the same way

More personal control over healthcare and the desire for more access to information drive consumer attitudes

Court rulings begin to swing toward categorizing pharma reps as hourly workers

The biopharma company’s annual report provides clarity to a confusing marketplace

Following are excerpts from the keynote presentation of Steven C. Anderson, president and CEO of the National Assn. of Chain Drug Stores, at its annual meeting, Palm Beach, FL, Apr. 25.

CMS will be changing reimbursement practices regardless of how healthcare reform plays out

Industry anticipates meaningful guidance from FDA on use of social media

Class-wide opioid REMS will affect four million patients and require cooperation of more than 25 drug manufacturers

More and more parts of the healthcare industry are connecting

The emergence of specialty pharmacies, with fundamental differences from other types of pharmacy providers, warrants the establishment of manufacturer relationships

Drug companies should keep a goal of effective communications as the priority in medical publications

FDA struggles with the new world of social media

New technologies are creating a powerful link between patients and healthcare providers. This Connected Health World has implications for pharmaceutical business practices

Aggressive cost competition and the continuing growth of generic substitution will separate retailers’ interests from manufacturers’

The desire to compare drugs’ efficacy is shifting from a purely medical decision to a financial one

Under the theme of personalized medicine, in vitro diagnostics will play an increasingly important role in new drug entries and new therapies